We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

106 hedge funds and large institutions have $115M invested in Rigel Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

886% more call options, than puts

Call options by funds: $887K | Put options by funds: $90K

0% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 34

0.28% less ownership

Funds ownership: 6.37% → 6.09% (-0.28%)

10% less funds holding

Funds holding: 118 → 106 (-12)

20% less capital invested

Capital invested by funds: $143M → $115M (-$28M)

65% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 17

Holders
106
Holders Change
-12
Holders Change %
-10.17%
% of All Funds
1.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
34
Reduced
34
Closed
17
Calls
$887K
Puts
$90K
Net Calls
+$797K
Net Calls Change
-$206K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$3.75M
2
VOYA Investment Management
VOYA Investment Management
Georgia
+$1.39M
3
SCM
Soleus Capital Management
Connecticut
+$752K
4
GCP
GSA Capital Partners
United Kingdom
+$737K
5
BCM
Bridgeway Capital Management
Texas
+$264K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$2.49M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.79M
3
Millennium Management
Millennium Management
New York
-$1.66M
4
TA
Tamarack Advisers
California
-$1.61M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$18.5M +$43.3K +3,600 +0.2%
SCM
2
Soleus Capital Management
Connecticut
$16M +$752K +62,500 +4%
BlackRock
3
BlackRock
New York
$15.6M -$246K -20,409 -1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$9.58M -$2.49M -206,908 -19%
Morgan Stanley
5
Morgan Stanley
New York
$7.54M +$3.75M +311,816 +81%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$5.03M +$95.3K +7,923 +2%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$3.83M +$169K +14,005 +4%
State Street
8
State Street
Massachusetts
$3.78M -$24.7K -2,053 -0.6%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$3.64M -$243K -20,208 -6%
Millennium Management
10
Millennium Management
New York
$3.36M -$1.66M -138,365 -31%
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$2.99M -$1.03M -85,470 -24%
N
12
Nuveen
North Carolina
$2.66M +$3.31K +275 +0.1%
VOYA Investment Management
13
VOYA Investment Management
Georgia
$2.22M +$1.39M +115,726 +129%
Macquarie Group
14
Macquarie Group
Australia
$1.73M – – –
Northern Trust
15
Northern Trust
Illinois
$1.64M +$5.1K +424 +0.3%
CM
16
CM Management
Florida
$1.62M – – –
SFM
17
Sphera Funds Management
Israel
$1.33M – – –
UOC
18
UBS O'Connor
Illinois
$1.24M +$150K +12,500 +12%
Renaissance Technologies
19
Renaissance Technologies
New York
$1.22M -$541K -44,930 -28%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$1.11M -$1.4M -116,440 -53%
GCP
21
GSA Capital Partners
United Kingdom
$1.05M +$737K +61,281 +171%
Charles Schwab
22
Charles Schwab
California
$933K – – –
BCM
23
Bridgeway Capital Management
Texas
$642K +$264K +21,920 +58%
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$639K -$10.8K -896 -1%
Goldman Sachs
25
Goldman Sachs
New York
$632K +$86.1K +7,158 +14%
1
2 3 4 5

RIGL Hedge Fund Activity: Q3 2023 in Review

106 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2023, worth a combined $115M — down 20% from $143M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of RIGL and 6 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 34 added.

The largest buyer was Morgan Stanley, adding an estimated $3.75M. The largest seller was Vanguard Group, cutting an estimated $2.49M.

  • 106 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2023, down from 118 in Q2 2023.
  • Funds reported $115M of Rigel Pharmaceuticals stock for Q3 2023, down 20% quarter-over-quarter.
  • 6 funds opened new Rigel Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of -11 holders.
  • The largest Rigel Pharmaceuticals buyer in Q3 2023 was Morgan Stanley, an estimated $3.75M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $2.49M sold.

Based on aggregated 13F filings for Q3 2023.